the aid library

Multi-country outbreak of cholera External Situation Report # 23, published 20 February 2025

World Health Organisation (WHO) (2025) C_WHO

Multi-country outbreak of cholera External Situation Report # 23, published 20 February 2025

Уход на дому за пациентами с подозрением на заражение или подтвержденным заболеванием COVID-19 и тактика ведения контактных лиц
recommended

World Health Organization WHO (2020) C_WHO

Этот документ представляет собой обновление рекомендаций «Уход на дому за пациентами с легкой формой заболевания COVID‑19 и тактика ведения контактных лиц», опубл� ... more

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust i ... more

Snakebite envenoming -- A strategy for prevention and control. Executive Summary

World Health Organization World Health Organization WHO (2019) C_WHO

Leaflet

The social context of schistosomiasis and its control

Brunn, B.; Aagaard-Hansen, J.; Watts, S. World Health Organization WHO (2008) C_WHO

Schistosomiasis is widely recognized as a disease that is socially determined. An understanding of the social and behavioural factors linked to disease transmission and control should play a vital role in designing policies and strategies for schistosomiasis prevention and control. To this must be a ... more

Test procedures for insecticide resistance monitoring in malaria vector mosquitoes

World Health Organization WHO (2016) C_WHO

2nd edition. WHO's recommendation has not changed: the standard WHO susceptibility tests should remain a primary method by which resistance is detected. However, it was considered necessary to update the existing resistance-monitoring procedures to also highlight the need for operationally meaningfu ... more

A toolkit for national dengue burden estimation

Brady, O. J. et all. World Health Organization WHO (2018) CC

The aim of this toolkit is to guide countries on how to best estimate their current burden of dengue by combining existing data from dengue surveillance systems with on-going research efforts to measure the community burden of dengue.

Formation sur le suivi et l’évaluation épidémiologique du traitement médicamenteux de masse pour l’élimination de la filariose lymphatique : guide des apprenants

World Health Organization World Health Organization WHO; Institutional research information sharing iris (2013) C_WHO

Formation sur le suivi et l’évaluation épidémiologique du traitement médicamenteux de masse pour l’élimination de la filariose lymphatique : guide des apprenants. Organisation mondiale de la Santé.

WHO neonatal resuscitation manikin technical specifications

World Health Organization WHO WHO (2021) CC

The United Nations Commission on Life-Saving Commodities (UNCLSC, 2012) defined 13 health products to end preventable deaths of woman and children. One of those 13 products is the neonatal resuscitator, is indispensable medical device to save newbor ... more

Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases

World Health Organization WHO (2018) C_WHO

This protocol provides an approach for public health authorities and investigators at all levels to plan for and conduct investigations of nonseasonal influenza and other emerging respiratory diseases and provides tips and reminders for linking the ... more

Psychological interventions implementation manual: Integrating evidence-based psychological interventions into existing services

World Health Organization WHO (2024) C_WHO

Evidence-based psychological interventions are an important part of health, social, protection and education services and can help increase access to effective mental health treatments and progressi ... more

G20 Shared Understanding on the Importance of UHC Financing in Developing Countries: Towards Sustainable and Inclusive Growth

G20 Health and Finance Ministers G20 (2019) CC

As a deliverable of the G20 Health and Finance Ministers' Meeting on June 28, 2019, ministers confirmed their commitment to this "G20 Shared Understanding."

Diseño y validación de una encuesta solo sobre triquiasis-tracomatosa: Grupo Consultivo estratégico y técnico para enfermedades tropicales desatendidas, Grupo de trabajo sobre Monitoreo y evaluación

World Health Organization World Health Organization WHO (2017) C_WHO

La quincuagésima primera Asamblea de la Salud Mundial aprobó la resolución WHA51.11 en 1998, que busca la eliminación mundial del tracoma como problema de salud pública para el 2020 (1). La estrategia recomendada para lograr ese objetivo está encapsulada por las siglas "SAFE", que represent ... more

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Healthy environments for healthy children

World Health Organization (WHO) (2010) C_WHO

This booklet presents key messages for action, summarized from a set of chapters on different environmental health issues, available at www.who.int/ ceh/publications/healthyenvironmentsforhealthychildren. The work is a result of an on-going partners ... more

The Expanded Special Project for Elimination of Neglected Tropical diseases — ESPEN

World Health Organization World Health Organization WHO (2023) C_WHO

While virtually unheard of in developed countries, NTDs are a group of medically diverse parasitic and bacterial infectious diseases common in tropical and subtropical areas. NTDs affect more than 1.5 billion people annually, causing death, blindness, disfigurement, chronic pain, cognitive impairmen ... more

Hand Hygiene Observation Form

World Health Organization WHO (2009) C_WHO

Evaluation of hand hygiene practices and related perception and knowledge at a health-care facility is one vital element of the strategy to improve hand hygiene. Continuous monitoring is very helpful in measuring the changes induced by implementatio ... more

Preventable Epilepsy: Taenia Solium Infection Burdens Economies, Societies and Individuals

World Health Organization World Health Organization WHO (2016) C_WHO

Burden of T. solium: Neurocysticercosis is a disease induced by T. solium larvae penetrating human tissues, especially the nervous system. Neurocysticercosis burdens economies, societies and individuals because of the impact of epilepsy on wages, health ... more